|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
19 Pt 2
|
|
pubmed:dateCreated |
2005-10-5
|
|
pubmed:abstractText |
A study was designed to define the therapeutic efficacy, safety, and toxicity of two sequential high-dose treatments of radioimmunotherapy with [131I]cG250 in patients with metastasized renal cell carcinoma. Here, we report the dosimetric analysis and the relationship between the development of a human antichimeric antibody response and altered pharmacokinetics.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
11
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
7178s-7186s
|
|
pubmed:dateRevised |
2011-7-29
|
|
pubmed:meshHeading |
pubmed-meshheading:16203819-Adult,
pubmed-meshheading:16203819-Aged,
pubmed-meshheading:16203819-Antibodies, Monoclonal,
pubmed-meshheading:16203819-Carcinoma, Renal Cell,
pubmed-meshheading:16203819-Disease Progression,
pubmed-meshheading:16203819-Dose-Response Relationship, Radiation,
pubmed-meshheading:16203819-Female,
pubmed-meshheading:16203819-Humans,
pubmed-meshheading:16203819-Iodine Radioisotopes,
pubmed-meshheading:16203819-Kidney Neoplasms,
pubmed-meshheading:16203819-Kinetics,
pubmed-meshheading:16203819-Male,
pubmed-meshheading:16203819-Middle Aged,
pubmed-meshheading:16203819-Neoplasm Metastasis,
pubmed-meshheading:16203819-Radioimmunotherapy,
pubmed-meshheading:16203819-Radiometry,
pubmed-meshheading:16203819-Recombinant Fusion Proteins
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Radioimmunotherapy with [131I]cG250 in patients with metastasized renal cell cancer: dosimetric analysis and immunologic response.
|
|
pubmed:affiliation |
Department of Nuclear Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. a.h.brouwers@nucl.umcg.nl
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
